GlaxoSmithKline (GSK) reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates of 24.21 pence on revenue of 7.20 billion pounds, in Q1 2018.
Analysts expect EPS of 26.04 pence on revenue of 7.17 billion pounds in Q2 2018, a 2.0% fall in revenue compared to Q2 2017.
The chart above shows analysts’ recommendations for GlaxoSmithKline stock over the last 12 months.
GlaxoSmithKline’s ADR (American depositary receipt) has fallen ~6.6% over the last 12 months, but it’s risen ~12.3% YTD (year-to-date) in 2018. Analysts’ estimates show that the stock has the potential to return ~5.7% over the next 12 months. Analysts’ recommendations show a 12-month target price of $42.13 per share compared to GSK’s price of $39.85 per share on May 25.
On May 29, five were analysts tracking GlaxoSmithKline’s ADR on the NYSE. Of these five analysts, one recommended a “strong buy,” while four recommend “holds” on the stock. No analysts recommended “sells” on the stock. The consensus rating for GlaxoSmithKline stands at 2.60, which represents a moderate “buy” for value investors.
On the London Stock Exchange, GlaxoSmithKline stock has reported an 8.2% fall in its price over the last 12 months, but it’s risen 13.4% YTD. There are 26 analysts tracking GlaxoSmithKline stock on the London Stock Exchange. Of these, four have recommended “strong buys,” six have recommended “buys,” 15 have recommended “holds,” and two have recommended “sells,” as we can see in the graph above. The consensus target price for GlaxoSmithKline stock is 2.50 pounds, representing a moderate “buy” for value investors.
Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!